Phase 3 N=404 Clinical Trial in Females for Female Pattern Hair Loss
Androgenetic Alopecia
Primary: Target Area Hair Count — 152.7; 158.6; 162.2; 175.7 hairs per centimeter squared — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=113 Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity
Dentine Hypersensitivity
Primary: Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Day 14 — -1.20; -0.37 Score on a scale — p=<0.0001
Phase 3 N=1,417 Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Primary: Annualized Relapse Rate — 0.401; 0.224; 0.198; 0.286 Relapses Per Year
Phase 3 N=10 Southern Bone & Joint Study - Brimless Sockets
Socket Designs of Transfemoral Amputees.
Primary: Gait
Phase 3 N=848 A Trial of Degarelix in Patients With Prostate Cancer
Prostate Cancer
Primary: Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) With Degarelix — 90.0 percentage of participants
Phase 3 N=15,526 An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
Acute Coronary Syndrome · Myocardial Infarction · Myocardial Ischemia
Primary: The Percentage of Patients With the Composite Endpoint of Cardiovascular Death, Myocardial Infarction, or Stroke — 7.4; 6.1; 6.1 Percentage of patients — p=0.020
Phase 3 N=1,234 Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Primary: Proportion of Subjects Relapsed — 0.461; 0.270; 0.260 Proportion of subjects,confirmed relapse
Phase 3 N=945 Flibanserin Versus Placebo in Premenopausal Women With HSDD
Sexual Dysfunctions, Psychological
Primary: Change From Baseline in the Frequency of Satisfying Sexual Events as Measured by the eDiary. — 1.2; 1.5; 0.9 events per month
Phase 3 N=98 Phase 3/Safety & Efficacy of Esomeprazole in Infants
Gastroesophageal Reflux Disease (GERD)
Primary: Number of Participants Discontinuing Due to Symptom Worsening in the Randomized Treatment Withdrawal Phase (Treatment Withdrawal Phase Endpoint) — 1; 6; 8; 12 Participants
Phase 3 N=65 Hyper- and Hypokalemic Periodic Paralysis Study
Hyperkalemic Periodic Paralysis · Hypokalemic Periodic Paralysis
Primary: HYP Attack Rate — 0.9; 4.8 attacks per week
Phase 3 N=33 Varenicline Treatment for Active Alcoholic Smokers
Smoking · Tobacco Dependence · Alcohol Dependence
Primary: Prolonged Smoking Abstinence at End of 12 Weeks of Varenicline Treatment — 6; 1 participants — p=0.034
Phase 3 N=282 Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients
Liver Transplant Recipient
Primary: Incidence Rate of Composite Efficacy Failure Defined as Treated Biopsy Proven Acute Rejection (tBPAR ), Graft Loss or Death — 2; 1; 3 Participants
Phase 3 N=42 A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Fasting Plasma Glucose (FPG) — -27.6 mg/dL
Phase 3 N=716 A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline (BL) in 0 to 24 Hour Weighted Mean Serial Forced Expiratory Volume in One Second (FEV1) at Day 84 — 0.166; 0.087 Liters — p=<0.001
Phase 3 N=706 A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in 24-hour Weighted-mean Serial FEV1 on Treatment Day 84 — 0.165; 0.091 Liters — p=<0.001